Inclusion Criteria:

diagnosis of essential hypertension

Exclusion Criteria:

• pregnancy, breast-feeding, unwilling to use effective contraception (if female of child-bearing potential).
• development of any condition in the preceding trial that could be worsened by T40/A10 or T80/A10.
• discontinuation from the preceding trial.
• known or suspected secondary hypertension.
• mean seated SBP >= 180 mmHg and/or mean seated DBP >= 120 mmHg at any visit.
• any clinically significant hepatic impairment or severe renal impairment
• bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant.
• clinically relevant hyperkalaemia.
• uncorrected volume or sodium depletion.
• primary aldosteronism.
• hereditary fructose or lactose intolerance.
• symptomatic congestive heart failure.
• patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or ARBs.
• any new drug or alcohol dependency since signing consent of the preceding trial.
• concurrent participation in another clinical trial or any investigational therapy since completing the preceding trial.
• hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve.
• known allergic hypersensitivity to any component of the formulations under investigation. (Includes known hypersensitivity to telmisartan or other ARBs or amlodipine or other dihydropyridine CCBs.)
• non-compliance with study medication (defined as <80% or >120%) during the preceding trial.
• administration of ARBs or dihydropyridine CCBs (apart from trial medication). any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine.